STEM-CELL TRANSPLANTATION; ACUTE KIDNEY INJURY; ERYTHROPOIESIS-STIMULATING AGENTS; RECOMBINANT-HUMAN-ERYTHROPOIETIN; RANDOMIZED CONTROLLED-TRIAL; GROUP CONSENSUS STATEMENT; NEWLY-DIAGNOSED MYELOMA; ZOLEDRONIC ACID; RENAL IMPAIRMENT; BONE-DISEASE

The European Myeloma Network provides recommendations for the management of the most common complications of multiple myeloma. Whole body low-dose computed tomography is more sensitive than conventional radiography in depicting osteolytic disease and thus we recommend it as the novel standard for the detection of lytic lesions in myeloma (grade 1A). Myeloma patients with adequate renal function and bone disease at diagnosis should be treated with zoledronic acid or pamidronate (grade 1A). Symptomatic patients without lytic lesions on conventional radiography can be treated with zoledronic acid (grade 1B), but its advantage is not clear for patients with no bone involvement on computed tomography or magnetic resonance imaging. In asymptomatic myeloma, bisphosphonates are not recommended (grade 1A). Zoledronic acid should be given continuously, but it is not clear if patients who achieve at least a very good partial response benefit from its continuous use (grade 1B).